Incidence and treatment-modifying impact of immune checkpoint inhibitor–associated peripheral edema: a systematic review and meta-analysis
Clicks: 1
ID: 315947
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #49 of 50 articles by views in jnci cancer spectrum
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
INTRODUCTION: Immune-related adverse events (irAEs) disrupt immune checkpoint inhibitor (ICI) therapy and impact quality of life. Peripheral edema is common among patients with cancer, however, the causality of peripheral edema can be unclear in the context of multidrug regimens. METHODS: PubMed/MEDLINE, Embase, and Web of Science were searched to identify Phase 3 RCTs evaluating ICIs reporting peripheral edema incidence. The incidence of edema was calculated according to AE, ICIs, and treatment patterns. A random-effects meta-analysis pooled odds ratios (ORs) of edema incidence between ICI and non-ICI groups. A systematic review characterizing the interventions for irAE peripheral edema was also conducted. RESULTS: From 58 RCTs (22590 patients), treatment-related (TRAE) peripheral edema (Grade 1 to 5) occurred in 2.80% (n = 195/6969) of patients receiving ICI monotherapy, 4.96% (n = 112/2257) receiving ICI with chemotherapy, and 8.73% (n = 205/2349) receiving ICI with targeted therapy. Meta-analysis showed ICI monotherapy had lower TRAE peripheral edema compared to chemotherapy (OR = 0.45, 95% CI [0.27,0.73], p = 0.001, I 2=69%) with lowest relative incidence among PD-1 vs chemotherapy (OR = 0.41, 95% CI [0.23,0.73], p = 0.003) and ICI vs taxane chemotherapy (OR = 0.32, 95% CI [0.18,0.58], p < 0.001). A systematic review of treatment outcomes for irAE peripheral edema among 40 patients (19 studies) revealed 82.5% (n = 33/40) of cases received glucocorticoid treatment and ICIs were permanently discontinued in 35% (n = 14/40). CONCLUSIONS: Peripheral edema is a rare but potentially serious adverse event associated with ICIs. ICIs likely confer less peripheral edema risk than taxane therapy. To avoid unnecessary treatment interruptions, treatment discontinuation requires careful consideration-particularly when edema develops following ICI combination therapy.
| Reference Key |
openalex_W7163566993
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Anneliese Markus, K Tsuchiya, Toshiaki Takahashi, Evelyn Elias, Mako Koseki, Yoshito Nishimura, Nicholas Rohs, Yu Fujiwara |
| Journal | jnci cancer spectrum |
| Year | 2026 |
| DOI |
10.1093/jncics/pkag058
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.